These results suggested the potential of Syr to attenuate inflammatory response, myocardial fibrosis, and oxidative stress for the treatment of DCM, and its mechanism of action is related to TGF-β/Smad2/3 and Keap1/Nrf2 signaling pathways. The gene discussed is NFE2L2; the disease is familial dilated cardiomyopathy.